The Worldwide Patient-Derived Xenograft/PDX Model Industry
30 Apr 2021
Dublin, April 30, 2021 (GLOBE NEWSWIRE) -- The "Patient-Derived Xenograft/PDX Model Market by Type (Mouse, Rat), Tumor Type (Gastrointestinal, Gynecological, Hematological), Application (Preclinical Drug Development, Biomarker analysis), End User (Pharma, Biotech, CROs) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
The global Patient-Derived Xenograft/PDX models market size is projected to reach USD 299 million by 2026 from USD 140 million in 2021, at a CAGR of 16.4% during the forecast period.
Market growth is driven mainly by factors such as growing demand for personalized medicine, continuous support for cancer research, and growth in pharma R&D. Rising demand for humanized PDX models is expected to provide growth opportunity for players in the PDX models market. However, the high cost of personalized PDX models, stringent guidelines regarding the ethical use of animals in cancer research, and limitations associated with PDX models are expected to restrain the growth of this market to a certain extent during the forecast period.
The preclinical drug development segment accounted for the highest growth rate in the PDX models market, by application, during the forecast period
The PDX models market is segmented into preclinical drug development, biomarker analysis, and basic cancer research. The preclinical drug development segment accounted for the highest growth rate in the PDX models market during the forecast period. This segment's high growth rate can be attributed to the rising number of clinical trials every year.
Contract research organizations segment accounted for the highest CAGR
Based on end users, the PDX models market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. During the forecast period contract research organizations accounted for the highest growth rate. The high growth rate in this segment can be attributed to the increasing number of pharmaceutical companies outsourcing their preclinical studies to CROs.
Rat models segment accounted for the highest CAGR
Based on type, the PDX models market is segmented into mice models and rat models. The rat models segment accounted for the highest growth rate during the forecast period. Growth in this market is mainly driven by the larger size of rats, which enhances surgical manipulation. Moreover, the development of immunodeficient rats will further drive the usage of rat models in PDX model generation.
Respiratory tumor models segment accounted for the highest CAGR
Based on tumor type, the PDX models market is segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models. The respiratory tumor models segment accounted for the highest growth rate during the forecast period. The key factor driving this segment's growth is the increasing incidence of lung cancers globally.
Asia Pacific: The fastest-growing country in the PDX models market
The PDX models market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Factors such as the rising R&D spending, growing public-private partnerships, and increasing government funding are factors driving the growth of the PDX models market in this region.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights4.1 PDX Models Market Overview4.2 North America: PDX Models Market, Market Share (2020)4.3 PDX Models Market Share, by End-user (2020)4.4 PDX Models Market: Geographic Growth Opportunities
5 Market Overview5.1 Introduction5.2 Market Dynamics5.2.1 Drivers5.2.1.1 Growing Demand for Personalized Medicine5.2.1.2 Continuous Support for Cancer Research from the Public & Private Sectors5.2.1.3 Rising Pharma R&D5.2.2 Restraints5.2.2.1 High Cost of Personalized PDX Models5.2.2.2 Stringent Guidelines for the Use of Animal Models in Cancer Research5.2.3 Opportunities5.2.3.1 Rising Demand for Humanized PDX Models5.2.4 Challenges5.2.4.1 Limitations of PDX Models5.3 Impact of the COVID-19 Outbreak on the Growth of the PDX Models Market5.4 Technological Analysis5.5 Pricing Analysis5.6 Value Chain Analysis5.7 Ecosystem Analysis of the PDX Models Market5.8 Porter'S Five Forces Analysis5.8.1 Threat of New Entrants5.8.2 Threat of Substitutes5.8.3 Bargaining Power of Buyers5.8.4 Bargaining Power of Suppliers5.8.5 Intensity of Competitive Rivalry5.9 Regulatory Analysis5.9.1 North America5.9.2 Europe5.9.3 Asia-Pacific5.9.3.1 China5.9.3.2 Japan5.9.3.3 India5.9.3.4 Australia5.9.4 Latin America5.9.5 Middle East & Africa5.10 Patent Analysis
6 PDX Models Market, by Type6.1 Introduction6.2 Mice Models6.2.1 Ease of Procurement and Wide Availability of Mice Models Drive the Growth of this Segment6.3 Rat Models6.3.1 Factors Such as Easier Surgical Manipulation and Larger Tumor Size Will Support Use of Rat Models
7 PDX Models Market, by Tumor Type7.1 Introduction7.2 Gastrointestinal Tumor Models7.2.1 Newly Developed Gastrointestinal Tumor Models Mimic the Tumor Better Than Previous Models7.3 Gynecological Tumor Models7.3.1 High Incidence of Target Cancers Has Driven Demand for Tumor Models7.4 Respiratory Tumor Models7.4.1 Rising Prevalence of Lung Cancer to Drive Market Growth7.5 Urological Tumor Models7.5.1 Companies Are Focusing on Expanding Their Portfolio for Urological Cancers7.6 Hematological Tumor Models7.6.1 New Strains Such as Nsg and Nog Have Increased the Life Span of Hematological Tumor Models7.7 Other Tumor Models
8 PDX Models Market, by Application8.1 Introduction8.2 Preclinical Drug Development8.2.1 Rise in Number of Clinical Trials Will Drive the Growth of this Segment8.3 Biomarker Analysis8.3.1 Growing Interest in Precision Medicine Will Contribute to the Demand for PDX Models for Biomarker Analysis8.4 Basic Cancer Research8.4.1 Rising Funding for Cancer Research Will Drive Market Growth in this Segment
9 PDX Models Market, by End-user9.1 Introduction9.2 Pharmaceutical & Biotechnology Companies9.2.1 Rising Collaboration Between Pharma & Biotech Companies for Developing Cancer Therapeutics9.3 Contract Research Organizations9.3.1 Rising Outsourcing of Drug Discovery Services Will Drive Market Growth9.4 Academic & Research Institutions9.4.1 Increase in Government Life Sciences R&D Expenditure Will Contribute to the Growth of this Segment
10 PDX Models Market, by Region10.1 North America10.2 Europe10.3 Asia-Pacific10.4 Latin America10.5 Middle East & Africa
11 Competitive Landscape11.1 Overview11.2 Market Evaluation Framework11.3 Market Share Analysis11.4 Revenue Share Analysis of Top Market Players11.5 Company Evaluation Quadrant11.5.1 Stars11.5.2 Emerging Leaders11.5.3 Pervasive11.5.4 Emerging Companies11.6 Company Evaluation Quadrant: Start-Ups/SMEs11.6.1 Progressive Companies11.6.2 Starting Blocks11.6.3 Responsive Companies11.6.4 Dynamic Companies11.7 Company Product Footprint11.8 Company Geographic Footprint11.9 Competitive Scenario11.9.1 PDX Models Market: Product & Service Launches, January 2018-February 202111.9.2 PDX Models Market: Deals, January 2019-February 202111.9.3 PDX Models Market: Other Developments, January 2018-February 2021
12 Company Profiles12.1 Key Market Players12.1.1 Jsr Corporation12.1.2 Wuxi Apptec12.1.3 The Jackson Laboratory12.1.4 Charles River Laboratories12.1.5 Champions Oncology12.1.6 Oncodesign12.1.7 Envigo12.1.8 Pharmatest Services12.1.9 Hera Biolabs12.1.10 EPO Berlin-Buch Gmbh12.1.11 Xentech12.1.12 Urosphere12.2 Other Players12.2.1 Abnova Corporation12.2.2 Genesis Biotechnology Group12.2.3 Explora Biolabs12.2.4 Biocytogen12.2.5 Living Tumor Laboratory12.2.6 Bioduro12.2.7 Aragen Life Sciences W.E.F12.2.8 Shanghai Lide Biotech
13 Appendix13.1 Discussion Guide13.2 Knowledge Store: Subscription Portal13.3 Available Customizations13.4 Related Reports13.5 Author Details
For more information about this report visit
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.